On April 15, 2026 Quanterix Corporation (Nasdaq: QTRX) reported plans to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026. Built on the integration of Akoya Biosciences’ spatial biology platform and Quanterix’s decades of ultra-sensitive, quantitative immunoassay development from the SIMOA technology, the Content Innovation Engine is organized around the hallmarks of cancer framework, giving researchers a systematic, biology-first approach to revealing more from every tissue section.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
It is supported by the end-to-end capabilities spatial biology needs to advance beyond discovery: world-class spatial instrumentation, and the assay design and reagent formulation expertise, quality systems, and manufacturing scale to support measurements that meet the requirements of translational and clinical applications.
"Spatial biology has fundamentally changed how we see cancer," said Everett Cunningham, President and CEO of Quanterix. "Akoya built a platform that gave researchers an entirely new way to study it. What Quanterix brings is the assay expertise, quality systems, and scale to carry that science further, into translational settings, into the clinic, into decisions that affect patients. The Content Innovation Engine is the first expression of what that combination makes possible."
IO60 Named Edison Award Finalist; Spike-In Module Deepens Immunotherapy Biology
The PhenoCode Discovery IO60 panel has been named a Finalist in the Edison Awards. At AACR (Free AACR Whitepaper), Quanterix will introduce a new IO60 Spike-In Module extending biological coverage into two high-priority areas: checkpoint therapy markers spanning PD-1/PD-L1, CTLA-4, and next-generation blockade; and tertiary lymphoid structure (TLS) markers, an emerging correlate of durable immunotherapy response.
ADC + IO: Combination Biology in a Single Tissue Section
New high-plex ADC content compatible with IO60 and PhenoCode Discovery panels on PhenoCycler-Fusion will enable co-measurement of ADC target expression and tumor immune contexture in a single tissue section. This addresses growing demand for combination biology readouts at the ADC-immunotherapy interface.
PhenoCode Molecular Barcoding Kit, Debuting at AACR (Free AACR Whitepaper), Early Access May 2026
Quanterix will introduce the PhenoCode Molecular Barcoding Kit at AACR (Free AACR Whitepaper), built on a new PhenoCode 2.0 chemistry. The kit enables researchers to barcode virtually any antibody of their choice with exceptional reliability and yield. Existing panels can be expanded into immuno-oncology, neuroscience, and beyond without adding complexity to the workflow. Early access begins May 2026. Attend the live in-booth presentation at Booth 2028 on April 20, 11:30 AM to 12:00 PM to learn more.
PhenoImager HT: Two New ADC Lung Cancer Panels, Available Now via Accelerator
The Accelerator Service Lab will present two new ADC lung cancer panels for PhenoImager HT at AACR (Free AACR Whitepaper). Building on the ADC breast cancer panel debut at AACR (Free AACR Whitepaper) 2025, both panels are available today as a fully managed service. Attend the live in-booth presentation at Booth 2028 on April 21, 11:30 AM to 11:45 AM for details.
Quanterix’s growing spatial biology community will also be represented at AACR (Free AACR Whitepaper) 2026, with 25+ posters from customers and collaborators presenting data generated on PhenoCycler-Fusion and PhenoImager HT across a range of cancer indications.
For more information visit: View Source
(Press release, Quanterix, APR 15, 2026, View Source [SID1234664416])